@article{article_337345, title={Does the use of corticosteroid nasal spray play a role in the development of central serous chorioretinopathy?}, journal={Anatolian Clinic the Journal of Medical Sciences}, volume={22}, pages={163–168}, year={2017}, DOI={10.21673/anadoluklin.337345}, author={Elbay, Ahmet and Yenigün, Alper and Özdemir, Hakan and Çalım, Ömer Faruk and Ekinci, Cansu and Çetinkaya, Rukiye}, keywords={Santral seröz koryoretinopati,koroid kalınlığı,retina pigment epiteli – Bruch membran kompleksi,kortikosteroid,nasal sprey}, abstract={<p class="MsoNormal" style="text-align:justify;line-height:150%;"> <b> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;" xml:lang="en-us">Aim: </span> </b> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;" xml:lang="en-us">
The aim of the present study is to investigate the effect of corticosteroid-containing
nasal spray on development of central serous chorioretinopathy (CSC)
development and thickness of choroid and Retinal pigment epithelium-Bruch
membrane complex ( </span> <span style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;">RPE-BM). </span> <span style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;"> <span lang="en-us" xml:lang="en-us"> </span> </span> </p> <p> </p> <p class="MsoNormal" style="text-align:justify;line-height:150%;"> <b> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;" xml:lang="en-us">Materials and Methods: </span> </b> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;" xml:lang="en-us"> Twenty-nine patients (18 female, 11 male) receiving
nasal mometasone spray were included in the study. Systolic blood pressure
(SBP), diastolic blood pressure (DBP), visual acuity, intraocular pressure and
choroidal and </span> <span style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;">RPE-BM </span> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;" xml:lang="en-us">thicknesses
were measured before and one week and one month after drug administration.
Optical coherence tomography sections were examined in terms of CSCdevelopment.
Measurements were made from the right eye. </span> </p> <p> </p> <p class="MsoNormal" style="text-align:justify;line-height:150%;"> <b> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;" xml:lang="en-us">Results: </span> </b> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;" xml:lang="en-us"> Central serous chorioretinopathy was not detected in any of the patients.
Mean choroidal thickness measurements did not show any statistically
significant changes between baseline values ​​and follow-up measurements: On
the temporal side 292.48±73.02 μm before the treatment, 296.83±79.09 μm at the
first week, 295.41±74.13 μm at the first month (p = 0.405); at the subfovea
360.62±92.44 μm at baseline, 364.04±93.65 μm at the first week, and
365.66±95.86 μm at the first month (p = 0.208) under the fovea; on the nasal
side, 282.86±96.11 μm at the beginning, 285.28±93.25 μm at the first week and
284.28±98.14 μm at the first month (p = 0.819). </span> <span style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;">RPE-BM </span> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;" xml:lang="en-us"> was measured as 21.65±2.86 μm at the beginning,
21.24±2.61 μm at the first week and 21.58±2.09 μm at the first month.
Differences were not statistically significant (p = 0.450). There was no
significant difference in intraocular pressure (p = 0.450), SBP (p = 0.257) and
DBP (p = 0.249) measurements. </span> </p> <p> </p> <p> </p> <p class="MsoNormal" style="text-align:justify;line-height:150%;"> <b> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;" xml:lang="en-us">Discussion and Conclusion: </span> </b> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;" xml:lang="en-us"> Further studies are needed to determine the incidence
of corticosteroid-induced SSR and cause-effect relationship between CSC
development and choroid or RPE-BM thickness. </span> </p> <p> </p>}, number={3}, publisher={Hayat Sağlık ve Sosyal Hizmetler Vakfı}